Entrada Therapeutics to Present at H.C. Wainwright BioConnect Investor Conference

Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company based in Boston, is making strides in developing groundbreaking treatments for patients by targeting intracellular mechanisms that have previously been difficult to address. On May 16, 2024, the company announced that its Chief Executive Officer, Dipal Doshi, will engage in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. This event is scheduled to take place at NASDAQ in New York, NY, on May 20, 2024, at 9:30 a.m. Eastern Time.

The session aims to provide insights into Entrada's innovative approaches and ongoing developments. For those interested, a live webcast of the event will be made available on the company’s website. Additionally, a recorded replay will be accessible for 90 days post-event.

Entrada Therapeutics is dedicated to revolutionizing patient care through the creation of a new class of medicines that can interact with intracellular targets. The company has developed Endosomal Escape Vehicle (EEV™)-therapeutics, a technology designed to facilitate the efficient delivery of various active compounds into cells across different organs and tissues. This technology promises a better therapeutic index and is adaptable and versatile, supporting a broad spectrum of treatment programs.

The company's technology focuses on delivering RNA, antibodies, and enzymes to treat numerous conditions, including neuromuscular, ocular, metabolic, and immunological diseases. Among its leading projects are oligonucleotide programs aimed at treating individuals with Duchenne muscular dystrophy, specifically those amenable to exon 44, 45, and 50 skipping. Moreover, Entrada has developed VX-670, a clinical-stage program targeting myotonic dystrophy type 1.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!